立普妥对老年充血性心力衰竭MS患者血清CRP和LDL-C的影响

目的探讨CRP水平和充血性心力衰竭（CHF）、代谢综合征（MS）程度之间的关系,以及应用立普妥对CHF代谢综合征预后的影响。方法观察120例CHF代谢综合征患者在常规应用心衰治疗药物的基础上,给予立普妥干预前后血清CRP和LDL-C的变化。另选30例无心衰MS患者为对照组。结果心衰代谢综合征患者CRP、LDL-C水平均明显高于无心衰代谢综合征患者（P〈0.05）相关分析显示CHF患者的CRP水平和心衰程度呈正相关（r=0.14,0.21,0.32,0.39,P〈0.05）。CHF患者的LDL-C水平和心衰程度亦呈正相关（r=0.21,0.33,0.46,0.50,P〈0.05）。药物干预组立普妥治疗前与治疗后比较,LDL-C水平有明显降低（P〈0.05）。常规治疗组治疗前与治疗后比较,LDL-C水平无明显变化（P〉0.05）。药物干预组患者给予立普妥干预治疗4,8周后比较CRP水平均有显著降低（P〈0.01）,且与应用时间的长短呈正相关（r=0.11,0.34,P〈0.05）;常规治疗组患者治疗前、后比较,CRP水平无明显变化（P〉0.05）。结论CRP可以作为CHF代谢综合征患者预后评估的重要指标之一。

Effect of Atorvastatin (Lipitor) on Serum C-reactive Protein and LDL-C in Elderly Patients With Congestive Heart Failure

Objective The study discussed the relation between CRP and heart failure degree,and effects that atorvastatin (Lipitor) brought to heart failure patients by observing CRP and LDL-C variation of patients who took heart failure drugs routinely before and after taking atorvastatin.Methods To observe the changes before and after serum CRP and LDL-C gaving atorvastat in to the 120 patients,on the basis of applying the routione medecine for CHF treament.Results Atorvastatin might reduce serum CRP and LDL-C level of CHF patient,which reduce coronary artery events and worsen of CHF in the long run.It is benefit to evaluate CHF prognosis.Conclusions CRP might be one of important indexet for evaluating CAD patients prognosisl.Atorvastatin could delay CHF developing and reducing CHF patients'coronary artey events.